These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 22763801)

  • 21. Olmesartan medoxomil in elderly patients with essential or isolated systolic hypertension : efficacy and safety data from clinical trials.
    Heagerty AM; Mallion JM
    Drugs Aging; 2009; 26(1):61-76. PubMed ID: 19102515
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined olmesartan, amlodipine, and hydrochlorothiazide therapy in randomized patients with hypertension: a subgroup analysis of the TRINITY study by age.
    Lewin AJ; Izzo JL; Melino M; Lee J; Fernandez V; Heyrman R
    Drugs Aging; 2013 Jul; 30(7):549-60. PubMed ID: 23549909
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of an olmesartan medoxomil-based treatment algorithm on systolic blood pressure in patients with stage 1 or 2 hypertension: a randomized, double-blind, placebo-controlled study.
    Kereiakes DJ; Maa JF; Shojaee A; Dubiel R
    Am J Cardiovasc Drugs; 2010; 10(4):239-46. PubMed ID: 20653330
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre study.
    Volpe M; Brommer P; Haag U; Miele C
    Clin Drug Investig; 2009; 29(1):11-25. PubMed ID: 19067471
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Triple-combination treatment with olmesartan medoxomil/amlodipine/ hydrochlorothiazide in Hispanic/Latino patients with hypertension: the TRINITY study.
    Lewin AJ; Kereiakes DJ; Chrysant SG; Izzo JL; Oparil S; Lee J; Fernandez V; Melino M
    Ethn Dis; 2014; 24(1):41-7. PubMed ID: 24620447
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination therapy with olmesartan medoxomil and hydrochlorothiazide: secondary analysis of the proportion of patients achieving recommended blood pressure goals from a randomized, double-blind, factorial study.
    Chrysant SG; Chavanu KJ; Xu J
    Am J Cardiovasc Drugs; 2009; 9(4):241-51. PubMed ID: 19655819
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antihypertensive efficacy and safety of olmesartan and ramipril in elderly patients with mild to moderate systolic and diastolic essential hypertension.
    Mallion JM; Omboni S; Barton J; Van Mieghem W; Narkiewicz K; Panzer PK; Puig JG; Stefanadis C; Zweiker R;
    Blood Press Suppl; 2011 Apr; 1():3-11. PubMed ID: 21091270
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of an olmesartan medoxomil-based treatment algorithm in patients with hypertension and type 2 diabetes: analysis of diurnal blood pressure control as assessed by 24-hour ambulatory blood pressure monitoring.
    Kereiakes DJ; Neutel J
    Ther Adv Cardiovasc Dis; 2010 Oct; 4(5):285-93. PubMed ID: 20801941
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Triple-Combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in black and non-black study participants with hypertension: the TRINITY randomized, double-blind, 12-week, parallel-group study.
    Chrysant SG; Littlejohn T; Izzo JL; Kereiakes DJ; Oparil S; Melino M; Lee J; Fernandez V; Heyrman R
    Am J Cardiovasc Drugs; 2012 Aug; 12(4):233-43. PubMed ID: 22799613
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Seated cuff blood pressure-lowering efficacy of an olmesartan medoxomil-based treatment regimen in patients with type 2 diabetes mellitus.
    Kereiakes DJ; Neutel JM
    Drugs R D; 2011 Sep; 11(3):251-7. PubMed ID: 21777013
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of an amlodipine/olmesartan treatment algorithm in patients with or without type 2 diabetes and hypertension (a secondary analysis of the BP-CRUSH study).
    Nesbitt SD; Shojaee A; Maa JF; Weir MR
    J Hum Hypertens; 2013 Jul; 27(7):445-52. PubMed ID: 23254596
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of amlodipine/olmesartan medoxomil ± hydrochlorothiazide in patients aged ≥ 65 or < 65 years with uncontrolled hypertension on prior monotherapy.
    Weir MR; Shojaee A; Maa JF
    Postgrad Med; 2013 Mar; 125(2):124-34. PubMed ID: 23816778
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systolic blood pressure reduction with olmesartan medoxomil versus nitrendipine in elderly patients with isolated systolic hypertension.
    Mallion JM; Heagerty A; Laeis P
    J Hypertens; 2007 Oct; 25(10):2168-77. PubMed ID: 17885562
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An olmesartan medoxomil-based treatment algorithm is effective in achieving 24-hour BP control in patients with type 2 diabetes mellitus, regardless of age, race, sex, or severity of hypertension: subgroup analysis of the BENIFICIARY study.
    Neutel JM; Kereiakes DJ;
    Am J Cardiovasc Drugs; 2010; 10(5):289-303. PubMed ID: 20712386
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study.
    Shimada K; Ogihara T; Saruta T; Kuramoto K;
    Clin Ther; 2010 May; 32(5):861-81. PubMed ID: 20685495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Blood pressure-lowering efficacy of an olmesartan medoxomil/hydrochlorothiazide-based treatment algorithm in elderly patients (age ≥65 years) stratified by age, sex and race: subgroup analysis of a 12-week, open-label, single-arm, dose-titration study.
    Neutel J; Kereiakes DJ; Stoakes KA; Maa JF; Shojaee A; Waverczak WF
    Drugs Aging; 2011 Jun; 28(6):477-90. PubMed ID: 21639407
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents. Olmesartan medoxomil versus antihypertensives.
    Ball KJ; Williams PA; Stumpe KO
    J Hypertens Suppl; 2001 Jun; 19(1):S49-56. PubMed ID: 11451215
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Placebo effect and efficacy of nebivolol in patients with hypertension not controlled with lisinopril or losartan: a phase IV, randomized, placebo-controlled trial.
    Weiss RJ; Stapff M; Lin Y
    Am J Cardiovasc Drugs; 2013 Apr; 13(2):129-40. PubMed ID: 23519546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension.
    Lee SE; Kim YJ; Lee HY; Yang HM; Park CG; Kim JJ; Kim SK; Rhee MY; Oh BH;
    Clin Ther; 2012 Mar; 34(3):552-568, 568.e1-9. PubMed ID: 22381711
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A placebo-controlled comparison of the efficacy and tolerability of candesartan cilexetil, 8 mg, and losartan, 50 mg, as monotherapy in patients with essential hypertension, using 36-h ambulatory blood pressure monitoring.
    Baguet JP; Nisse-Durgeat S; Mouret S; Asmar R; Mallion JM
    Int J Clin Pract; 2006 Apr; 60(4):391-8. PubMed ID: 16620350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.